ment on CLD. According to a clinical protocol, the criteria for randomization wcrc: 1 ) ventilator dependency at a postnatal age of 10 d. 2 ) fraction of inspired oxygen 20.3 and/or PIP 2 16 cm H 2 0 . 3) no radiologic evidence of pneumonia. no clinical or laboratory signs of local and systcnlic infection (immature/total ncutrophil ratio < 0.2. serum C-reactive protcin < 0.6 mg/dL, negative blood and trachcal cultures). Eight infants died during the first 10 d of life. Of the remaining 59 neonates. 24 met the criteria mentioned above and were randomly assigned to treatment with Dxm on d 10 (carly treatment group) or d 16 (late treatment group). Because measurements of plasma C5a levels wcre done only in the last three infants, five additional patients entered the study after June 18. 1992. Thus. in eight infants. levels of C5a wcre determined in both plasma and lung cfllucnt fluid. The results of the C5a concentrations in the respiratory fluids were nearly identical in these additional patients when compared with the original study group. Two infants of the total group wcre excludcd from analysis because there was evidence of bacterial contamination of trachcobronchial aspirate fluid. Of the remaining 27 patients. 14 had been randomized into the early trcatment group and 13 infants into the late treatment group. Ten of the 67 infants with birth weight < I200 g who were still intubated at d 10 postnatal age but did not meet the ventilatory criteria noted above served as a control group for the Dxm treatment groups. The cffccts of Dxm were invcstigatcd within each treatmcnt group. Furthermore, both groups were comparcd at d 15 of postnatal age, whcn the late treatment group served as a control group for the effects of Dxnl 5 d after initiation of therapy in the early trcatmcnt group. Dxm was given intravenously every 12 h in divided doscs ovcr a period of 28 d. Thc maximal dose was 0.5 mg/kg/d for the first 3 d and 0.3 mg/kg/ d for the next 3 d. This dose was reduced by 10% until a dose of 0.1 mg was reached on d 24. which was given every second day until d 28. In 2 1 of 27 Dxm-treated infants. RDS was diagnosed clinically and confirmed by L/S ratio analysis. All infants with RDS wcrc treated with natural porcine surfactant, as previously described (22). The study was approved by the hospital ethics committee. Informed consent of the parents was obtained.
Srir)~/)lir~,q (?f1rriclrcohrot1ci~ial rr.s~~irrrlc,/llrirl. Tracheobronchial aspiration was performed in a standardizcd manner at least three times daily, by instillation of 0.5 m L of 0.9% NaCl into the endotracheal tube. Suction catheters were inserted slightly beyond the distal tip of the tube, and lung and airway secretions were suctioned and collcctcd in sterile specimen traps (Vygon, Ecoucn. France). Tracheobronchial aspiratc fluid was diluted with 0.9% saline to a total volume of 0.5 mL, centrifuged at 3000 rpm for 5 min, and cell-free supernatants were frozcn at -30°C for later assay. During 24 h. one specimen was obtaincd in each 8-h period. Immediately before analysis, the three samples for 1 d werc pooled. The lung eflluent fluid of all infants was cultured for microbiologic analysis twice weekly; additionally. bacterioscopic exaniinations were performed.
PI'INSIIIN . s r i r~~~l c~.
For determination of CSa/CSa(des Arg) in plasma. 500 of blood was obtaincd by venipuncture and was collected into a syringe containing dipotassium-EDTA. The plasma was separated from the blood cells by centrifugation (10 min/1000 x g ) and was stored at -30°C within 1 I1 after puncture.
ELIS.4 ji)r C.5rr/CS~(rlev :lr;y) r~~rrrrlli~rr~iorl. The quantitation of CSa/CSa(des Arg) was performed as described previously (2 1 ). In this ELISA, an MAb is used with specificity for a neoantigenic determinant that is present on CSa/CSa(des Arg) but not on the native precursor protcin C5. In brief, wells of microtitcr plates were coated with I00 ofanti-C5a MAb C17/5 (40 ccg/rnL) in carbonate buffer. After blocking of nonspecific binding sites, 100-pL samples urere applied per well. Purified C5a or plasma samplcs that were diluted at lcast 2-fold in PBS-Tween-20 mM EDTA wcre allowed to bind to the solid phase for 2 I1 and were detected by adding, in sequence. the second biotinylated antiC5a MAb G25/2 ( 1 ccg/mL PBS-Tween) and a 1000-fold dilution of strcptavidin-peroxidase in PBS-Tween, both incubation steps lasting 1 11. Incubation pcriods urere stopped by repeated wash cycles with PBS-Tween. C5a determinations were carried out by the colorimetric analysis of pcroxidase-mediated hydrolysis of 2 mM 2.2'-a7ino-di-(3-~tl1ylbcnz-thinzoline sulfonatc) in the prcsencc of 2.5 mM H 2 0 2 using a nlicroplate photomctcr. read at 410 nm.
..llhluuin rrs.srrjq. Albumin in plasma and trachcobronchial aspirate fluid was mcasured by single radial immunodiffusion (NOR-. VLC-and LC-partigcn, Behring. Marburg, Germany).
C'orlc.c~ntrtr~iori.s c~/'c.orl.stitlrctlt.s it1 lrrrlg i;[/llrcnt ,/llrirl. T o avoid errors due to the sampling proccdure, concentrations of constituents in tracheobronchial aspirate fluid are usually related to albumin concentrations. However, this is only correct whcn albumin concentrations in respiratory fluids are constant over a certain period of time. Bccause albumin conccntrations were markedly afl'cctcd by Dxm treatment. we chose to express concentrations of all constituents of lung eflluent as weight unit/mL of fluid. The suction technique was standardized as mentioned above. The recovered volume of pulmonary effluent by a single tracheal suction did not change in the week bcforc and after Dxm treatment (155 f 60 \'cJr:slr.s 158 f 55 pL).
:lrlrrI~:si.s ( ! f L / S rrrfio. Amniotic fluid or tracheal aspirates were obtained immediately after birth and frozcn at -30°C. Analysis of L/S ratio was done in modification as previously described (23).
S~ri!i.stical r1n(rlj*si.s. Bccause of the skewed distribution of the results, data of C5a nlcasurements are exprcsscd as median (25th-75th percentile) and analyzed for statistical significance using the Mann-Whitncy U test and the Wilcoxon signed-rank tcst, as appropriate. Clinical data are expressed as mean + SD and analyzed for statistical significance by means of the paired and unpaired I tcst. A p value < 0.05 was considered statistically significant. gases within normal ranges are shown in Table I . According to the inclusion criteria, they were higher in infants at risk for CLD compared with controls and decreased after both early and late Dxrn treatment. 
DISCUSSION
In this study, we provide evidence that the complement component C5a may be involved in the recruitment of inflammatory cells into the airways of preterm infants during the developmcnt of CLD. C5a conccntrations in pulmonary emuent of infants at risk for CLD were higher compared with control infants. After treatment with Dxm, C5a concentrations significantly decreased. These results correspond well with the neutrophil count in respiratory fluids of ventilated preterm infants. Infants who later developed CLD had increascd numbers of ncutrophils in lung emuent fluid compared with controls ( I , 2). After treatment with Dxm, neutrophil count in airway secretions was reduced (18). We have previously shown that infants at risk for CLD have high chemotactic activity of lung effluent fluid, and that this chemotactic activity was reduced after Dxm treatment (3). High chemotactic activity of airway fluids is a common feature of inflammatory lung diseases (24). Because C5a is a potent chemoattractant, it may considerably contribute to neutrophil influx into the airways. Additionally, C5a has marked effects on microvascular permeability (25). Whether C5a that is present in respiratory fluids alters lung permeability depends on where and how it is generated.
The source of C5a detectable in ainvay secretions is not clear. It may be of local or systemic origin. A systemic complement activation has been postulated for the pathogenesis of ARDS. In animal models, systemic activation can induce neutrophil accumulation in the lungs and an increased pulmonary epithelial permeability (26). However, only half of human patients with ARDS showed evidence for systcmic complement activation, but nine of 10 patients had C5a in the bronchoalveolar lavage fluid (9). Systemic activation of the complement system does not seen1 to be necessary for the observed pulmonary efl'ccts of C5a. Direct instillation of C5a into the lungs of rabbits is also associatcd with a massive influx of ncutrophils into the ainvays (27). Neutrophil pulmonary recruitment mediated by C5a thus may occur via local activation of complement components. Although the liver is the major site of synthesis of complement proteins. components of both pathways are produced in lung tissue as well. C2. C4, and factor B have been found to be produced by macrophages (28, 29) and type I1 alveolar epithelial cells (29). Additionally, type I1 cells are capable of synthesizing of C3 and C5 (30). These factors secreted by cells of the alveolar wall arc thought to contribute to local inflammatory rcsponscs in the lung. Neutrophils attracted by other chemotactic active material can clcave locally produced C5 to chcmotactic C5a by elastasc release (31) and thus amplify the inflammatory response. Free elastase activity has been detected in pulmonary effluent alrcady in the carly stages of RDS ( 1, 32)
The complcmcnt systenl may also be activated by trauma in the immature lung. As shown in our patients. C5a levels are closely related to barotrauma. indicated by PIP and high oxygen concentrations. In prcterm infants with surfactant deficiency. positive pressure ventilation rapidly initiates epithelial disruption of the ainvays (33). Hyperoxia also damages the pulmonary tissue. Trauma can induce complement activation via the contact and the kinin systems (34). Furthcrmorc. exposure of complement conlponents present in interstitial or airway-lining fluid to subcellular membrane fragments can lead to an activation of the cascade (35). Whcn activatcd locally, C5a may considerably contribute to increascd lung permeability, which has been shown to be associatcd with CLD (20).
C5a is also detectable in plasma. In the blood of healthy individuals, there is a low-grade generation of C5a that is rapidly bound to white blood cells. C5a levels measured in plasma of our infants were comparable to those of healthy adults (21). Because lung microvascular permeability is increascd in infants with CLD, high levels of C5a in lung cflluent fluid thus may result from incrcased plasma leakage. This explanation would imply that C5a is not the primary agent that alters lung permcability. The cause of the increased pulnlonary microvascular permeability in CLD is not known, but it is thought to be due to an inflammatory process that is associated with the development of the disease (36). Mediators other than C5a with marked effects on microvascular permeability have been detected in the ainvays of infants with CLD and could be responsible for the increased permeability observed (37).
Our data show that C5a conccntrations in lung cflluent fluid are significantly decreased after Dxm treatment. In contrast, C5a concentrations in plasma are not affected by Dxm. This finding nlay indicate that Dxm exerts diffcrcnt effects on the local
